

## Mannheim, September 7, 2021

### 17. ELN Symposium with 20. KNL Symposium

Congress Center Rosengarten, Mannheim

	<b>Mahler 1</b>	<b>Chairs/Contributors</b>
<b>8:00 - 9:30</b>	<b>Session 1 WP4 CML</b> EURO SKI Final Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid Leukemia (SUSTRENIM) European CML Blast Crisis registry	<b>F. Guilhot, A. Hochhaus, L. Stenke</b>  M. Pfirrmann  F. Pane A. Brioli
9:30 - 9:45	Coffee Break	
<b>9:45 - 11:15</b>	<b>Session 2: WP5 AML</b>  Update renewal ELN MRD recommendations <ul style="list-style-type: none"> <li>- Molecular</li> <li>- Flow</li> <li>- Clinical</li> </ul> Update ELN recommendation unfit AML patients Collaboration with EHA	<b>G. Ossenkoppele, C. Thiede</b>   C. Thiede J. Cloos M. Heuser L. Amaurillo K. Döhner
11:15 - 11:30	Break	
<b>11:30 - 13:00</b>	<b>Session 3: HARMONY/HARMONY PLUS</b>  Welcome and Update HARMONY <ul style="list-style-type: none"> <li>15' - Results of Delphi surveys for COS Definition</li> <li>15' - Building a HARMONY Added Value Framework for hematologic malignancies: a comparative analysis of existing tools</li> <li>15' - Results of the research project on CLL</li> </ul> HARMONY PLUS <ul style="list-style-type: none"> <li>15' - The data we need from you in HARMONY / HARMONY PLUS &amp; the road ahead to make them useful for us and affordable for you.</li> <li>15' - Clonal hierarchy in CML.</li> </ul> Concluding remarks	<b>J.M. Hernandez, L. Bullinger</b>  J.M. Hernández   K. Lang  T. Berezcky L. Scarfò  TBC T. Ernst L. Bullinger
<b>13:00 - 14:00</b>	<b>Lunch</b>	
<b>14:00 - 15:30</b>	<b>Session 4: WP8 MDS/MDS-Right</b>  1. Welcome / Introduction <ul style="list-style-type: none"> <li>a) Minutes previous meeting</li> </ul> 2. Report EUMDS Registry <ul style="list-style-type: none"> <li>a) General overview EUMDS</li> <li>b) Progress of substudies and MDS-RIGHT activities               <ul style="list-style-type: none"> <li>- ..... highlight 2-3 substudies</li> </ul> </li> </ul> 3. Report of the ELN MDS Flow working group 4. Progress of the Trial Platform: EMSCO, (planned) trials 5. EuroBloodNet – MDS activities 6. IMI-2: Harmony - MDS activities	<b>T. de Witte</b>   T. de Witte   T. de Witte   TBC U. Platzbecker TBC TBC

	7. Update on the MDS Hub / Guideline update SES /	TBC
	8. Transplant studies: to be discussed with Marie Robin	M. Robin
	9. New Grant applications	T. de Witte
	a) Horizon Europe 2021-22	
	10. Closure of the meeting	T. de Witte
15:30 - 16:00	Coffee Break	
<b>16:00 - 17:15</b>	<b>General Assembly and Summary reports</b>	
17:15 - 17:30	Break with <b>Group photo</b>	
<b>17:30 - 18:00</b>	<b>ELN Merit Awards</b>	<b>R. Hehlmann</b>
5'	Francois Guilhot	
5'	Jerzy Holowiecki	
5'	Andrzej Hellmann	
5'	Fabrizio Pane	
5'	Sante Tura (in absentia)	
<b>18:00 - 20:00</b>	<b>Session 13: Keynote lectures</b>	<b>R. Hehlmann, D. Hoelzer</b>
20'	Genetic homogeneity of populations in central Europa as determined by tissue typing	W. Jędrzejczak
20'	Major achievements within the MDS-Right project	T. de Witte
20'	The HARMONY Data Platform	M. van Speybroeck
20'	Using the HARMONY data platform to answer research questions in the field of AML	L. Bullinger
20'	The Corona vaccination in Israel	M. Mittelman TBC
<b>20:00</b>	<b>Working dinner in the foyer</b>	
	<b>Mahler 2</b>	<b>Chairs/Contributors</b>
<b>8:00 - 9:30</b>	<b>Session 5: WP6 ALL</b>	<b>D. Hoelzer, S. Chiaretti</b>
	Ponatinib for the treatment of Ph-like ALL, from bench to bedside	S. Chiaretti
	Ph+ ALL: clinical results of changing TKI if no CMR	O. Gavrilina
	Outcome of the Ph+ ALL in the GMALL Studies	H. Pfeifer, F. Lang
	Treatment of Elderly ALL patients focusing on Immunotherapy	D. Hoelzer
	Venetoclax and HMA in R/R T-ALL	G. Isinova
	Chemo-free approach for newly diagnosed Ph+ ALL	S. Chiaretti
	The Moscow ALL Studies	E. Parovichnikova
9:30 - 9:45	Coffee Break	
<b>9.45 – 11.15</b>	<b>Session 8: WP10 Immunophenotyping</b>	<b>M.C. Béné, G. Zini</b>
	Update on virtual slide review in hematological malignancies	G. Zini
	Update on the WP10 morphology faculty	G. Zini
	A new exciting new marker for T-lineage proliferations	I. Marinov
	Update on unsupervised flow cytometry analysis	M.C. Béné
	Update on IVDR	M.C. Béné
11:15 - 11:30	Break	
<b>11:30 - 13:00</b>	<b>Session 7: WP9 MPN</b>	<b>T. Barbui</b>

New data on Second Wave of COVID-19 in MPN (ELN study)  
DOACs in MPN. The need for a clinical trial.  
Should we treat PV irrespectively  
of the thrombotic risk (ELN recommendations)?

T. Barbui  
M. Griesshammer  
  
M. Marchetti

13:00 - 14:00 Lunch

**14:00 - 15:30 Session 6: WP7 CLL**

A. Rawstron, P. Ghia

15' Forum on MRD in CLL  
ERIC overview  
30' ERIC flow cytometry approach -  
30' Discussion on possible updates of the recommendations  
15' Summary and future plans towards revised recommendations

P. Ghia  
A. Rawstron  
All  
A. Rawstron, P. Ghia

**Mahler 3**

**Chairs/Contributors**

**8:00 - 9:30 Session 9: WP12/13 MRD/NGS**

**T. Haferlach, C. Thiede**

Biological impact and synthetic lethal therapeutic vulnerabilities  
of del(11q) and concurrent gene mutations in CLL  
New approaches to MRD by NGS: ELN guidelines 2021  
Panel, Exome, WGS or WTS in routine?

M. Quijada-Álamo  
M. Heuser  
N. Nadarajah

9:30 - 9:45 Coffee Break

**9:45 - 11:15 Session 10: WP14 Transplantation**

**J. Apperley, D. Niederwieser**

GvHD after the REACH2 study. Do we need new recommendations?  
GvHD-App  
Use of artificial intelligence in stem cell transplantation

D. Niederwieser  
TBC  
D. Neumann

**13:00 - 14:00 Lunch**

**14:00 - 15:30 Session 11: WP17 Open Statistical Session**

**M. Pfirrmann**

Everybody can attend and ask statistical questions which will be  
answered on the spot

